# US 2014/0271667 A1 · Methods and Compositions for Neoadjuvant Therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271667 A1
- Document ID: US20140271667A1
- Status: Published application
- Kind: A1
- Application number: 14/211,394
- Filed: 2014-03-14
- Published: 2014-09-18
- Earliest claimed: 2013-03-15
- Assignees: The Wistar Institute of Anatomy and Biology
- Applicants: The Wistar Institute of Anatomy and Biology
- Inventors: Dario C. Altieri; Young Chan Chae
- Web page: https://patentgrep.com/patent/US20140271667A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/66: Phosphorus compounds
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method for inhibiting tumor cell migration or metastasis of a cancer in a mammalian subject comprises one or more of the steps of administering to a subject a therapeutically effective amount of a composition comprising a molecule that: suppresses focal adhesion kinase (FAK) activity or phosphorylation; suppresses ULK1 kinase activity; suppresses activation or signaling of the mTORC1 (Ser757) pathway; activates AMPK; activates FIP200; or activates LKB1, in a cancer cell. Still another method of inhibiting tumor cell migration involves inhibiting phosphorylation of ULK1 on Ser757 in subjects with lung cancer. Suppressing activation or signaling of the mTORC1 (Ser757) pathway in subjects is in one aspect useful in treating lung cancer.

## Claims

### Claim 1

A method for inhibiting tumor cell migration in a mammalian subject comprising:
(a) inhibiting, suppressing or down-regulating focal adhesion kinase (FAK) activity, expression, or phosphorylation of FAK in a cancer or tumor cell;
(b) inhibiting, suppressing or down-regulating ULK1 kinase activity, expression or phosphorylation of ULK1 on Ser757 in a cancer or tumor cell;
(c) inhibiting, suppressing or down-regulating activation, expression or signaling of the mTORC1 (Ser757) pathway in a cancer or tumor cell; or
(d) inhibiting, suppressing or down-regulating activity or expression of TRAP1 in a cancer or tumor cell;
(e) increasing, stimulating or activating AMPK activity or expression in a cancer or tumor cell;
(f) increasing, stimulating or activating LKB1 activity or expression in a cancer or tumor cell;
(g) increasing, stimulating or activating FIP200 activity, expression or phosphorylation in a cancer or tumor cell.

### Claim 2 (depends on 1)

The method according to claim 1, further comprising administering to a subject a therapeutically effective dose of at least one of:
(a) a composition comprising a molecule that inhibits, suppresses or down-regulates focal adhesion kinase (FAK) activity, expression or phosphorylation of FAK in a cancer cell.
(b) a composition comprising a molecule that inhibits, suppresses or down-regulates ULK1 kinase activity or expression;
(c) a composition comprising a molecule that inhibits, suppresses or down-regulates activation, expression or signaling of the mTORC1 (Ser757) pathway;
(d) a compositions comprising a molecule that inhibits, suppresses or down-regulates activity or expression of TRAP1;
(e) a composition comprising a molecule that increases, stimulates or activates AMPK activity or expression;
(f) a composition comprising a molecule that increases, stimulates or activates LKB1 activity or expression; and
(g) a composition comprising a molecule that increases, stimulates or activates FIP200 activity or expression or phosphorylation.

### Claim 3 (depends on 2)

The method according to claim 2, wherein said composition (b) suppresses phosphorylation of ULK1 on Ser757 in subjects with lung cancer.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the composition (c) is administered to subjects with lung cancer.

### Claim 5 (depends on 2)

The method according to claim 2, wherein the compositions (c) and (e) adjust the ratio of the AMPK pathway to mTORC 1 pathway in favor of the AMPK pathway.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the cancer is a glioblastoma a prostate adenocarcinoma, a lung adenocarcinoma, non-small cell lung adenocarcinoma, squamous cell carcinoma, liver cancer, breast adenocarcinoma or melanoma.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the subject has an established malignancy.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the administration occurs at a selected time during the course of cancer therapy.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the administration is part of a protocol of neoadjuvant therapy.

### Claim 10 (depends on 2)

The method according to claim 2, wherein the composition comprises Gamitrinib or an antibody to FAK, ULK1, mTORC1, or TRAP1.

### Claim 11 (depends on 2)

The method according to claim 2, further comprising administering the suboptimal dose of the composition prior to or during a course of chemotherapy or radiation to reduce the size of an existing primary tumor.

### Claim 12 (depends on 2)

The method according to claim 2, further comprising administering a suboptimal dose of the composition prior to or during surgery performed to debulk or remove a primary tumor.

### Claim 13 (depends on 2)

The method according to claim 2, comprising administering the suboptimal dose of the composition after surgery performed to debulk or remove a primary tumor.

### Claim 14 (depends on 2)

The method according to claim 2, further comprising administering the suboptimal dose of the composition prior to or during a second or repeated course of chemotherapy or radiation.

### Claim 15 (depends on 14)

The method according to claim 14 wherein the second or repeated course is post-surgery.

### Claim 16 (depends on 2)

The method according to claim 2, further comprising administering a continuous course of a suboptimal a dose of the composition to a patient from prior to a first round of pre-surgical chemotherapy, during and after surgery, and prior to and after a second round of post-surgical chemotherapy.

### Claim 17 (depends on 2)

The method according to claim 2, further comprising administering periodic suboptimal doses of the composition to a patient in need thereof, wherein the suboptimal doses are administered at suitable intervals prior to a first round of pre-surgical chemotherapy or radiation, after surgery, and prior to and after a second or repeated course of post-surgical chemotherapy or radiation.

### Claim 18

A therapeutic composition for inhibiting tumor migration in a mammalian subject comprising one or more of Gamitrinib, an antibody to FAK, an antibody to ULK1, an antibody to mTORC1, an antibody to TRAP1, or a nucleic acid molecule that expresses in a host cell a target selected from AMPK, FIP200 or LKB1

### Claim 19

A therapeutic composition for inhibiting tumor migration in a mammalian subject comprising one or more of a nucleic acid molecule that bind to a target selected from FAK, ULK1, mTORC1, TRAP1, AMPK, FIP200 or LKB1.
